Improving outcomes in hyperphosphataemia.

Area of Science:

• Nephrology
• Pharmacology
• Bone Metabolism

Background:

• Hyperphosphatemia is a common complication in end-stage renal disease (ESRD).
• Phosphate binders are crucial for managing hyperphosphatemia in ESRD patients.
• Concerns exist regarding potential bone toxicity of lanthanum, similar to aluminum.

Purpose of the Study:

• To evaluate the safety and efficacy of lanthanum carbonate as a phosphate binder in ESRD patients.
• To assess the long-term effects of lanthanum carbonate on bone health in dialysis patients.
• To compare the bone effects of lanthanum carbonate with calcium carbonate.

Main Methods:

• Preclinical studies assessing lanthanum's phosphate-binding capacity and absorption.
• Animal studies using lanthanum carbonate in healthy and nephrectomized models.
• A Phase III clinical trial involving bone biopsies from dialysis patients treated with lanthanum carbonate or calcium carbonate.

Main Results:

• Lanthanum carbonate demonstrates high phosphate-binding capacity and is well-tolerated.
• Lanthanum absorption is minimal, and elimination is primarily via the biliary route, independent of renal function.
• Animal studies showed no direct bone toxicity; effects on mineralization were secondary to phosphate depletion and reversible.
• Clinical trial patients on lanthanum carbonate did not exhibit aluminum-like bone toxicity (osteomalacia, adynamic bone disease).

Conclusions:

• Lanthanum carbonate is an effective and safe phosphate binder for hyperphosphatemia in ESRD patients.
• Lanthanum does not pose an increased risk of bone accumulation or toxicity in patients with chronic renal failure.
• Long-term treatment with lanthanum carbonate does not lead to adverse bone health outcomes comparable to aluminum toxicity.